Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10327241 | 1.00 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL10327556 | 0.83 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL26663164 | 0.82 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL30380313 | 0.82 | TDP1 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL13214411 | 0.81 | CA14 (0.34) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL3021763 | 0.81 | CA14 (0.34) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL26663996 | 0.81 | CA14 (0.37) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL26663905 | 0.81 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL26599408 | 0.79 | CA14 (0.36) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL24290892 | 0.78 | CA14 (0.35) | HDAC6HDAC1HDAC2CA14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8444955-B2 | Radiofluorination methods | GE HEALTHCARE LIMITED (GB) | 2013-05-21 | — | — | US | disclosed |
| US-8444955-B2 | Radiofluorination methods | GE HEALTHCARE LIMITED (GB) | 2013-05-21 | — | — | US | disclosed |
| US-8444955-B2 | Radiofluorination methods | GE HEALTHCARE LIMITED (GB) | 2013-05-21 | — | — | US | disclosed |
| US-8216548-B2 | Radiofluorination methods | GE HEALTHCARE AS (NO) | 2012-07-10 | — | — | US | disclosed |
| US-8216548-B2 | Radiofluorination methods | GE HEALTHCARE AS (NO) | 2012-07-10 | — | — | US | disclosed |
| US-8216548-B2 | Radiofluorination methods | GE HEALTHCARE AS (NO) | 2012-07-10 | — | — | US | disclosed |
| US-20100196270-A1 | RADIOFLUORINATION METHODS | GE HEALTHCARE AS (NO) | 2010-08-05 | — | — | US | disclosed |
| US-20100196270-A1 | RADIOFLUORINATION METHODS | GE HEALTHCARE AS (NO) | 2010-08-05 | — | — | US | disclosed |
| US-20100034740-A1 | RADIOFLUORINATION METHODS | GE HEALTHCARE AS (NO) | 2010-02-11 | — | — | US | disclosed |
| US-20100034740-A1 | RADIOFLUORINATION METHODS | GE HEALTHCARE AS (NO) | 2010-02-11 | — | — | US | disclosed |
| US-20100034740-A1 | RADIOFLUORINATION METHODS | GE HEALTHCARE AS (NO) | 2010-02-11 | — | — | US | disclosed |
| WO-2009035959-A2 | RADIOFLUORINATION METHODS | GE HEALTHCARE LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008083191-A2 | RADIOFLUORINATION METHODS | GE HEALTHCARE AS (NO) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196270-A1 | RADIOFLUORINATION METHODS | CYP2F1, CYP4F2, CYP4F3 | HDAC6 492/4885HDAC1 2890/4885HDAC2 3075/4885 |
| US-20100034740-A1 | RADIOFLUORINATION METHODS | CYP2F1, CYP4F2, CYP4F3 | HDAC6 492/4885HDAC1 2890/4885HDAC2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.